Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia

Akio Hiraki, Hiroshi Ueoka, Akihiro Bessho, Yoshihiko Segawa, Nagio Takigawa, Katsuyuki Kiura, Kenji Eguchi, Toshiyuki Yoneda, Mitsune Tanimoto, Mine Harada

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

BACKGROUND. Parathyroid hormone-related protein (PTH-rP) is a major cause of tumor-induced hypercalcemia (TIH) and frequently is found to be elevated in serum of patients with TIH. In the current study, the authors examined the usefulness of PTH-rP measurement at the time of first presentation in the follow-up of lung carcinoma patients with TIH. METHODS. The authors retrospectively studied 23 of 1149 lung carcinoma patients who were found to have TIH at the time of first presentation for the correlation between serum PTH-rP and the development of bone metastases and survival compared with lung carcinoma patients without TIH who were matched by gender, age, Eastern Cooperative Oncology Group performance status, histological type of tumor, and stage of the disease. RESULTS. Twenty-three lung carcinoma patients with TIH demonstrated significantly increased serum levels of PTH-rP (mean ± standard error [SE], 84.1 ± 16.5 pmol/L) compared with control patients without TIH (mean ± SE, 36.2 ± 2.0 pmol/L) at the time of first presentation, (P <0.001). In these hypercalcemic patients, patients whose serum PTH-rP was > 150 pmol/L (n = 16) were found to have a significantly increased rate of bone metastases (71.4% vs. 12.5%; P = 0.01) and decreased survival (median survival of 1.4 months vs. 5.4 months; P <0.015) compared with patients whose serum PTH-rP was <150 pmol/L (n = 7). CONCULUSIONS. The data from the current study suggest that serum PTH-rP as determined at the time of first presentation is a useful indicator of not only hypercalcemia but also bone metastasis and eventual survival in patients with lung carcinoma.

Original languageEnglish
Pages (from-to)1706-1713
Number of pages8
JournalCancer
Volume95
Issue number8
DOIs
Publication statusPublished - Oct 15 2002

Fingerprint

Parathyroid Hormone-Related Protein
Hypercalcemia
Neoplasm Metastasis
Carcinoma
Bone and Bones
Lung
Survival
Neoplasms
Blood Proteins
Bone Development
Serum

Keywords

  • Bone metastases
  • Hypercalcemia
  • Interleukin-6 (IL-6)
  • Lung carcinoma
  • Parathyroid hormone-related protein (PTH-rP)
  • Prognosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. / Hiraki, Akio; Ueoka, Hiroshi; Bessho, Akihiro; Segawa, Yoshihiko; Takigawa, Nagio; Kiura, Katsuyuki; Eguchi, Kenji; Yoneda, Toshiyuki; Tanimoto, Mitsune; Harada, Mine.

In: Cancer, Vol. 95, No. 8, 15.10.2002, p. 1706-1713.

Research output: Contribution to journalArticle

Hiraki, A, Ueoka, H, Bessho, A, Segawa, Y, Takigawa, N, Kiura, K, Eguchi, K, Yoneda, T, Tanimoto, M & Harada, M 2002, 'Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia', Cancer, vol. 95, no. 8, pp. 1706-1713. https://doi.org/10.1002/cncr.10828
Hiraki, Akio ; Ueoka, Hiroshi ; Bessho, Akihiro ; Segawa, Yoshihiko ; Takigawa, Nagio ; Kiura, Katsuyuki ; Eguchi, Kenji ; Yoneda, Toshiyuki ; Tanimoto, Mitsune ; Harada, Mine. / Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. In: Cancer. 2002 ; Vol. 95, No. 8. pp. 1706-1713.
@article{e594d493e77b4175a56fcff93187d133,
title = "Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia",
abstract = "BACKGROUND. Parathyroid hormone-related protein (PTH-rP) is a major cause of tumor-induced hypercalcemia (TIH) and frequently is found to be elevated in serum of patients with TIH. In the current study, the authors examined the usefulness of PTH-rP measurement at the time of first presentation in the follow-up of lung carcinoma patients with TIH. METHODS. The authors retrospectively studied 23 of 1149 lung carcinoma patients who were found to have TIH at the time of first presentation for the correlation between serum PTH-rP and the development of bone metastases and survival compared with lung carcinoma patients without TIH who were matched by gender, age, Eastern Cooperative Oncology Group performance status, histological type of tumor, and stage of the disease. RESULTS. Twenty-three lung carcinoma patients with TIH demonstrated significantly increased serum levels of PTH-rP (mean ± standard error [SE], 84.1 ± 16.5 pmol/L) compared with control patients without TIH (mean ± SE, 36.2 ± 2.0 pmol/L) at the time of first presentation, (P <0.001). In these hypercalcemic patients, patients whose serum PTH-rP was > 150 pmol/L (n = 16) were found to have a significantly increased rate of bone metastases (71.4{\%} vs. 12.5{\%}; P = 0.01) and decreased survival (median survival of 1.4 months vs. 5.4 months; P <0.015) compared with patients whose serum PTH-rP was <150 pmol/L (n = 7). CONCULUSIONS. The data from the current study suggest that serum PTH-rP as determined at the time of first presentation is a useful indicator of not only hypercalcemia but also bone metastasis and eventual survival in patients with lung carcinoma.",
keywords = "Bone metastases, Hypercalcemia, Interleukin-6 (IL-6), Lung carcinoma, Parathyroid hormone-related protein (PTH-rP), Prognosis",
author = "Akio Hiraki and Hiroshi Ueoka and Akihiro Bessho and Yoshihiko Segawa and Nagio Takigawa and Katsuyuki Kiura and Kenji Eguchi and Toshiyuki Yoneda and Mitsune Tanimoto and Mine Harada",
year = "2002",
month = "10",
day = "15",
doi = "10.1002/cncr.10828",
language = "English",
volume = "95",
pages = "1706--1713",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia

AU - Hiraki, Akio

AU - Ueoka, Hiroshi

AU - Bessho, Akihiro

AU - Segawa, Yoshihiko

AU - Takigawa, Nagio

AU - Kiura, Katsuyuki

AU - Eguchi, Kenji

AU - Yoneda, Toshiyuki

AU - Tanimoto, Mitsune

AU - Harada, Mine

PY - 2002/10/15

Y1 - 2002/10/15

N2 - BACKGROUND. Parathyroid hormone-related protein (PTH-rP) is a major cause of tumor-induced hypercalcemia (TIH) and frequently is found to be elevated in serum of patients with TIH. In the current study, the authors examined the usefulness of PTH-rP measurement at the time of first presentation in the follow-up of lung carcinoma patients with TIH. METHODS. The authors retrospectively studied 23 of 1149 lung carcinoma patients who were found to have TIH at the time of first presentation for the correlation between serum PTH-rP and the development of bone metastases and survival compared with lung carcinoma patients without TIH who were matched by gender, age, Eastern Cooperative Oncology Group performance status, histological type of tumor, and stage of the disease. RESULTS. Twenty-three lung carcinoma patients with TIH demonstrated significantly increased serum levels of PTH-rP (mean ± standard error [SE], 84.1 ± 16.5 pmol/L) compared with control patients without TIH (mean ± SE, 36.2 ± 2.0 pmol/L) at the time of first presentation, (P <0.001). In these hypercalcemic patients, patients whose serum PTH-rP was > 150 pmol/L (n = 16) were found to have a significantly increased rate of bone metastases (71.4% vs. 12.5%; P = 0.01) and decreased survival (median survival of 1.4 months vs. 5.4 months; P <0.015) compared with patients whose serum PTH-rP was <150 pmol/L (n = 7). CONCULUSIONS. The data from the current study suggest that serum PTH-rP as determined at the time of first presentation is a useful indicator of not only hypercalcemia but also bone metastasis and eventual survival in patients with lung carcinoma.

AB - BACKGROUND. Parathyroid hormone-related protein (PTH-rP) is a major cause of tumor-induced hypercalcemia (TIH) and frequently is found to be elevated in serum of patients with TIH. In the current study, the authors examined the usefulness of PTH-rP measurement at the time of first presentation in the follow-up of lung carcinoma patients with TIH. METHODS. The authors retrospectively studied 23 of 1149 lung carcinoma patients who were found to have TIH at the time of first presentation for the correlation between serum PTH-rP and the development of bone metastases and survival compared with lung carcinoma patients without TIH who were matched by gender, age, Eastern Cooperative Oncology Group performance status, histological type of tumor, and stage of the disease. RESULTS. Twenty-three lung carcinoma patients with TIH demonstrated significantly increased serum levels of PTH-rP (mean ± standard error [SE], 84.1 ± 16.5 pmol/L) compared with control patients without TIH (mean ± SE, 36.2 ± 2.0 pmol/L) at the time of first presentation, (P <0.001). In these hypercalcemic patients, patients whose serum PTH-rP was > 150 pmol/L (n = 16) were found to have a significantly increased rate of bone metastases (71.4% vs. 12.5%; P = 0.01) and decreased survival (median survival of 1.4 months vs. 5.4 months; P <0.015) compared with patients whose serum PTH-rP was <150 pmol/L (n = 7). CONCULUSIONS. The data from the current study suggest that serum PTH-rP as determined at the time of first presentation is a useful indicator of not only hypercalcemia but also bone metastasis and eventual survival in patients with lung carcinoma.

KW - Bone metastases

KW - Hypercalcemia

KW - Interleukin-6 (IL-6)

KW - Lung carcinoma

KW - Parathyroid hormone-related protein (PTH-rP)

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0037108289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037108289&partnerID=8YFLogxK

U2 - 10.1002/cncr.10828

DO - 10.1002/cncr.10828

M3 - Article

C2 - 12365018

AN - SCOPUS:0037108289

VL - 95

SP - 1706

EP - 1713

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 8

ER -